Literature DB >> 8769687

Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls.

L P van de Vijver1, R Steyger, G van Poppel, J M Boer, D A Kruijssen, J C Seidell, H M Princen.   

Abstract

Autoantibodies against oxidized low-density lipoprotein (LDL) have been reported to be associated with atherosclerosis. However, data are not consistent. We compared the titres of autoantibodies to malondialdehyde-modified LDL in three groups, a case group with angiographically documented severe coronary stenosis (> 80% stenosis in at least 1 vessel, n = 47), a hospital control group with minor stenosis on the coronary angiography (< 50% stenosis in all three major vessels, n = 47) and a healthy population control group with no history of coronary heart disease (n = 49). Age ranged from 26 to 68 years. Subjects were frequency-matched for gender distribution and storage time of the blood samples. No relevant differences in autoantibody titre between case and control groups were found. The mean autoantibody titres (+/- S.D.) were 1.44 +/- 1.82, 1.46 +/- 1.40 and 1.62 +/- 1.95 for cases, hospital controls and population controls, respectively. No correlations were found between autoantibody titre and age, number of cigarettes smoked and LDL or total cholesterol. Autoantibody titres were correlated with body mass index (r = 0.2) and high-density lipoprotein (HDL) (r = -0.2). Odds ratios (OR) were calculated by tertiles of autoantibody titres for the hospital control group and the population control group, respectively. Age-adjusted OR (95% confidence interval) for medium and high compared to low autoantibody titre were 0.76 (0.27-2.14) and 1.09 (0.39-2.95) for the comparison between cases and hospital controls and 1.09 (0.39-3.07) and 0.90 (0.32-2.56) for the comparison between cases and population controls. Adjustment for gender, body mass index, smoking habits and HDL yielded essentially the same results. This study does not support an association between autoantibody titres to oxidized LDL and the extent of coronary stenosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769687     DOI: 10.1016/0021-9150(95)05759-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients.

Authors:  Eva C Fernvik; Daniel F J Ketelhuth; Momtchilo Russo; Magnus Gidlund
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

3.  Reducing oxidized lipids to prevent cardiovascular disease.

Authors:  Ngoc-Anh Le
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

4.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 5.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

6.  Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study.

Authors:  Qi Chen; Steven E Reis; Candace Kammerer; Wendy Craig; Dennis M McNamara; Richard Holubkov; Barry L Sharaf; George Sopko; Daniel F Pauly; C Noel Bairey Merz; M Ilyas Kamboh
Journal:  J Lipid Res       Date:  2011-01-20       Impact factor: 5.922

7.  Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans.

Authors:  Peter Steer; Johannes Hulthe; Jonas Miligård; Dennis M Sarabi; Samar Basu; Bengt Vessby; Lars Lind
Journal:  Lipids       Date:  2002-12       Impact factor: 1.880

Review 8.  Oxidized low-density lipoprotein.

Authors:  Sampath Parthasarathy; Achuthan Raghavamenon; Mahdi Omar Garelnabi; Nalini Santanam
Journal:  Methods Mol Biol       Date:  2010

9.  [Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndromeand systemic lupus erythematosus].

Authors:  B Roch; S Kopprasch; J Pietzsch; H-E Schröder
Journal:  Z Rheumatol       Date:  2004-08       Impact factor: 1.372

Review 10.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.